Answers are grounded in this paper and cite their sources.
Case report examines Lu-PSMA-617 monotherapy outcome in metastatic hormone-sensitive prostate cancer, highlighting treatment alternatives.
Giri et al. present a case report involving a patient with metachronous low-volume metastatic hormone-sensitive prostate cancer (mHSPC) who declined standard treatments such as androgen deprivation therapy (ADT), androgen receptor pathway inhibitors (ARPI), and taxane chemotherapy because of
No takes yet. Share an insight, caveat, or question.
Hadaschik et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: